Clinical Efficacy of Modified Qingqi Huatan Wan in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Syndrome of Phlegm-heat Obstructing Lung and Effect on Serum TNF-α, IL-8 and MMP-9
10.13422/j.cnki.syfjx.20182212
- VernacularTitle: 清气化痰丸加减治疗慢性阻塞性肺疾病急性加重期痰热壅肺证的临床疗效及对血清TNF-α,IL-8,MMP-9的影响
- Author:
Rui LIU
1
;
Ti-bao HOU
1
;
Jia HE
1
;
Chuan-dong YE
1
Author Information
1. Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China
- Publication Type:Research Article
- Keywords:
acute exacerbation of chronic obstructive pulmonary disease;
syndrome of phlegm-heat obstructing lung;
modified Qingqi Huatan Wan;
interleukin-8 (IL-8);
matrix metalloproteinase-9 (MMP-9)
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(9):31-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the clinical efficacy of modified Qingqi Huatan Wan in treatment of acute exacerbation of chronic obstructive pulmonary disease (syndrome of phlegm-heat obstructing lung) and investigate its effects on serum tumor necrosis factor-alpha (TNF-α),interleukin-8(IL-8) and matrix metalloproteinase-9(MMP-9).Method: Sixty-four patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) were randomly divided into control group (32 cases) and treatment group (32 cases) by random number table.The control group was treated with routine western medicine therapy according to the guidance and disease conditions.Based on treatment in control group,patients in treatment group also received modified Qingqi Huatan Wan.The treatment course was 14 days for both groups.The scores of traditional Chinese medicine (TCM) syndrome,chronic obstructive pulmonary disease (COPD) assessment test (CAT),and modified version of the British Medical Research Council's Respiratory Questionnaire (mMRC),pulmonary function,blood gas analysis indicators,levels of serum TNF-α,IL-8 and MMP-9,clinical efficacy and safety were evaluated and compared once before treatment and 14 d after treatment.Result: The total clinical effective rate was 96.67% in treatment group,higher than 76.67% in control group (χ2=5.192,P<0.05).After treatment,scores of TCM syndrome,CAT and mMRC were reduced in both groups (P<0.05),and the scores in treatment group were all lower than those in control group (P<0.05).Levels of forced expiratory volume in one second (FEV1),percent of FEV1 in predicted value (FEV1%),and ratio of FEV1 to forced vital capacity (FEV1/FVC) were increased in both groups after treatment (P<0.05),and the above levels in treatment group were higher than those in control group (P<0.05).After treatment,oxygen saturation (SaO2) and partial pressure of oxygen (PaO2) were increased in both groups,while partial pressure of carbon dioxide (PaCO2) was decreased (P<0.05),and SaO2 and PaO2 in treatment group were higher than those in control group,while PaCO2 was lower than that in control group (P<0.05).After treatment,serum TNF-α,IL-8 and MMP-9 were decreased in both groups (P<0.05),and the levels in treatment group were lower than those in control group (P<0.05).Conclusion: Modified Qingqi Huatan Wan can control the symptoms safely and ameliorate pulmonary function,reduce the levels of serum TNF-α,IL-8,MMP-9 and inflammation in treatment of AECOPD.
